ASX Linkedin Twitter               

 

Clinical Trials – Phase 1 MITCI

Status: Recruiting Patients

A Phase 1b trial entitled MITCI (Melanoma Intra-Tumoral Cavatak and Ipilimumab) to investigate the use of CAVATAK® in combination with Ipilimumab (Yervoy®) in patients with advanced melanoma is underway at Providence Cancer Centre in Portland, Oregon; Oncology Specialists Institute in Chicago, Illinois and John Wayne Cancer Institute in Santa Monica, California.

The trial is designed to evaluate the safety and tolerability of the established dose of intratumoural CAVATAK in combination with Yervoy® in 26 patients with late-stage melanoma for whom Yervoy® would be considered the standard of care.

Investigators will also assess evidence of anti-cancer activity, including response rates and bio-markers of anti-tumour immunity.

For further information about this trial, please visit the Clinical Trial website at:ClinicalTrials.gov Identifier: NCT02307149

Click here for the latest news on the MITCI study

Viralytics Limited
Suite 305, Level 3, 66 Hunter Street
Sydney NSW 2000 Australia
T: +61 (0)2 9988 4000 F: +61 (0)2 8068 6038

© Viralytics Limited 2017
This information does not take your circumstances into account. Read the relevant ASX releases, financial reports and prospectuses before making an investment decision. Shares in Viralytics Limited, ABN 12 010 657 351, are traded on the Australian Stock Exchange (ASX:VLA) and on the over-the-counter market (OTC: VRACY).